Chartwell Investment Partners LLC grew its stake in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 8.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 107,023 shares of the company’s stock after acquiring an additional 8,732 shares during the period. Chartwell Investment Partners LLC’s holdings in Roche Holdings AG Basel were worth $4,636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of RHHBY. Riverbridge Partners LLC grew its holdings in Roche Holdings AG Basel by 3.6% in the 2nd quarter. Riverbridge Partners LLC now owns 660,039 shares of the company’s stock valued at $28,590,000 after buying an additional 22,699 shares in the last quarter. Bath Savings Trust Co boosted its position in shares of Roche Holdings AG Basel by 11.4% in the second quarter. Bath Savings Trust Co now owns 9,329 shares of the company’s stock valued at $405,000 after acquiring an additional 954 shares during the period. Canandaigua National Corp acquired a new position in shares of Roche Holdings AG Basel in the second quarter valued at about $763,000. Confluence Investment Management LLC bought a new position in Roche Holdings AG Basel during the second quarter worth about $894,000. Finally, Fulton Bank N.A. raised its stake in Roche Holdings AG Basel by 123.7% in the 1st quarter. Fulton Bank N.A. now owns 15,721 shares of the company’s stock worth $638,000 after purchasing an additional 8,693 shares in the last quarter. Institutional investors own 0.30% of the company’s stock.
Shares of RHHBY opened at $43.10 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.04 and a debt-to-equity ratio of 0.35. Roche Holdings AG Basel ADR has a 52-week low of $33.30 and a 52-week high of $46.63. The business’s fifty day moving average is $44.21 and its 200-day moving average is $42.63.
Roche Holdings AG Basel Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.